title: Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.
authors.affiliation: Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
authors.forename: V
authors.initials: V
authors.lastname: Ribrag
authors.forename: M
authors.initials: M
authors.lastname: Ghosn
authors.forename: J
authors.initials: J
authors.lastname: Guimares
authors.forename: C
authors.initials: C
authors.lastname: Theodore
authors.forename: M
authors.initials: M
authors.lastname: Azab
authors.forename: M
authors.initials: M
authors.lastname: Ostronoff
authors.forename: M
authors.initials: M
authors.lastname: Mahjoubi
authors.forename: A
authors.initials: A
authors.lastname: Moran
authors.forename: J
authors.initials: J
authors.lastname: Pico
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide